On July 5th, Shenzhen Stock Exchange issued a supervision letter on Harbin Gloria Pharmaceuticals and related responsible persons. On January 31st, the company disclosed the "2023 Performance Forecast", which expects a net income attributable to shareholders of the listed company of 0.2 billion yuan to 0.24 billion yuan in 2023. On April 20, 2024, the company disclosed the "2023 Annual Report", and the audited net income for 2023 was 0.12 billion yuan. There is a significant difference between the expected net profit disclosed in the performance forecast and the audited net profit disclosed in the annual report, which has not been corrected in a timely manner, making the performance forecast inaccurate. The company's above behavior violates the regulations of the Shenzhen Stock Exchange. The chairman of the company, Hu Jin, and the general manager and financial director, Guo Leifeng, failed to fulfill their duties and perform their integrity and diligence obligations, and have major responsibilities for the company's violations, which violates the regulations.
业绩预告与年报数据差异较大且未及时修正，誉衡药业及董事长等收深交所监管函
There is a significant difference between the performance forecast and the annual report data, and it has not been promptly corrected. Harbin Gloria Pharmaceuticals and the chairman have received supervision letters from the Shenzhen Stock Exchange.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.